These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15808446)

  • 1. [New treatments of atopic dermatitis].
    Taïeb A; Boralevi F
    Arch Pediatr; 2005 Apr; 12(4):491-7. PubMed ID: 15808446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
    de Bruin-Weller MS; Bruijnzeel-Koomen CA
    Ned Tijdschr Geneeskd; 2005 May; 149(20):1096-100. PubMed ID: 15932135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
    Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atopic dermatitis management with tacrolimus ointment (Protopic).
    Kapp A; Allen BR; Reitamo S
    J Dermatolog Treat; 2003; 14(Suppl 1):5-16. PubMed ID: 14522634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis.
    Bos JD
    Eur J Dermatol; 2003; 13(5):455-61. PubMed ID: 14693489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
    Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
    J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus ointment: new preparation. Too many unknowns.
    Prescrire Int; 2004 Jun; 13(71):86-9. PubMed ID: 15233141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.
    Singalavanija S; Noppakun N; Limpongsanuruk W; Wisuthsarewong W; Aunhachoke K; Chunharas A; Wananukul S; Akaraphanth R
    J Med Assoc Thai; 2006 Nov; 89(11):1915-22. PubMed ID: 17205874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safety of topical tacrolimus and pimecrolimus in children with atopic dermatitis].
    Rodríguez Orozco AR; Ruiz Reyes H; Marín Hernández D
    Rev Alerg Mex; 2005; 52(4):171-6. PubMed ID: 16268186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
    Eichenfield LF; Thaci D; de Prost Y; Puig L; Paul C
    Dermatology; 2007; 215 Suppl 1():3-17. PubMed ID: 18174689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
    Hebert AA
    Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
    Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
    Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life].
    Sunderkötter C; Weiss JM; Bextermöller R; Löffler H; Schneider D
    J Dtsch Dermatol Ges; 2006 Apr; 4(4):301-6. PubMed ID: 16638059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use.
    Paller AS; Eichenfield LF; Kirsner RS; Shull T; Jaracz E; Simpson EL;
    Pediatrics; 2008 Dec; 122(6):e1210-8. PubMed ID: 19015204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pimecrolimus in dermatology: atopic dermatitis and beyond.
    Gisondi P; Ellis CN; Girolomoni G
    Int J Clin Pract; 2005 Aug; 59(8):969-74. PubMed ID: 16033622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mode of topical immunomodulators in the immunological network of atopic dermatitis.
    Novak N; Kwiek B; Bieber T
    Clin Exp Dermatol; 2005 Mar; 30(2):160-4. PubMed ID: 15725246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis.
    Langley RG; Eichenfield LF; Lucky AW; Boguniewicz M; Barbier N; Cherill R
    Pediatr Dermatol; 2008; 25(3):301-7. PubMed ID: 18577032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pimecrolimus 1% cream for the treatment of atopic dermatitis.
    Wolff K
    Skin Therapy Lett; 2005 Oct; 10(8):1-6. PubMed ID: 16292456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
    Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y
    Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy.
    Werfel T
    J Dtsch Dermatol Ges; 2009 Sep; 7(9):739-42. PubMed ID: 19650820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.